BeiGene Approved to Produce anti-PD-1 in New Guangzhou Biologics Facility

Beijing's BeiGene was approved to manufacture the company's approved anti-PD-1 antibody at its new Guangzhou facility. With construction starting in 2017, the facility boasts 8,000 liters of capacity for producing biologic drugs and one million square feet of floor space. The anti-PD-1, tislelizumab, will be the first drug to be made at BeiGene's new plant. In January, BeiGene announced a $2.2 billion deal with Novartis to commercialize tislelizumab in countries outside of Greater China. More details.... Stock Symbols: (NSDQ: BGNE; HK: 06160) (NYSE: NVS) Share this with colleagues: // //